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Abstract: Activation of neutrophils is a critically important component of the innate immune
response to bacterial and chemical stimuli, and culminates in the “neutrophil burst”, which facilitates
neutrophil phagocytosis via the release of superoxide anion radical (O2−) from NADPH oxidase.
Excessive and/or prolonged neutrophil activation results in substantial tissue injury and increases
in vascular permeability—resulting in sustained tissue infiltration with neutrophils and monocytes,
and persistent vasomotor dysfunction. Cardiovascular examples of such changes include acute and
chronic systolic and diastolic heart failure (“heart failure with preserved ejection fraction”), and the
catecholamine-induced inflammatory disorder takotsubo syndrome. We have recently demonstrated
that B-type natriuretic peptide (BNP), acting via inhibition of activation of neutrophil NADPH
oxidase, is an important negative modulator of the “neutrophil burst”, though its effectiveness in
limiting tissue injury is partially lost in acute heart failure. The potential therapeutic implications of
these findings, regarding the development of new means of treating both acute and chronic cardiac
injury states, are discussed.
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1. Introduction
1.1. Neutrophil Activation, Vascular and Myocardial Inflammation
Neutrophils, as a pivotal component of the innate immune system, make fundamental
contributions to host defense against invading micro-organisms. The most important aspect of this role
is the phagocytic function of neutrophils, consisting of the engulfing of bacteria into lysosomes, within
which they are exposed to potentially lethal oxidative stress. The latter is engendered by a transient
process usually termed the “neutrophil burst,” whereby activation of the neutrophil isoform of NADPH
oxidase results in the production of large quantities of the superoxide (O2−) anion radical, together
with secondary increases in the generation of hydrogen peroxide and hypochlorous acid (HOCl) [1].
This “neutrophil burst” is associated with a transient but marked increase in neutrophil oxygen uptake
and utilization (the “respiratory burst”), and is also characterised by cytokine release, the activation
of monocytes and macrophages, the increased release of reactive oxygen species (ROS) such as O2−
into the extracellular space, the formation of neutrophil extracellular traps (NETs), and eventually
the apoptosis of neutrophils [2]. NET formation is initiated by the ejection of neutrophil nuclear
chromatin, and may be facilitated by the formation of HOCl—via activation of the neutrophil enzyme
myeloperoxidase [3]. Termination of the inflammatory process initiated in association with neutrophil
activation potentially begins at the time of neutrophil apoptosis, thus leading to what is normally a
brief but potent phagocytic response.
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The purpose of this review is to shed light on some of the factors recently recognised to modulate
the extent of an acute “neutrophil burst”, and also the timing of resolution of this inflammatory
response. In doing so, we will focus on the implications of neutrophil activation in acute forms of
(non-infective) cardiovascular disease states, and particular forms of impaired left ventricular function.
In particular, we will examine growing evidence that B-type natriuretic peptide (BNP)—which is
increasingly released from the myocardium in heart failure and myocardial inflammatory states—is a
substantial modulator of neutrophil activation and associated ROS production, as well as the potential
therapeutic significance of this discovery.
One of the critically important aspects of the process of neutrophil activation is that a component
of the resultant extracellular inflammatory functional disturbance induces the erosion of the vascular
endothelial glycocalyx (a process known as glycocalyx shedding), largely via activation of a variety of
matrix metalloproteinases [4]. Glycocalyx shedding, which can be detected and quantitated in vivo
by assay of plasma concentrations of various glycocalyx components (e.g., sindecan-1), distorts
vascular rheology, and results in the adhesion of neutrophils, monocytes and platelets to the damaged
glycocalyx, as well as an increase in vascular permeability and potential infiltration of neutrophils and
monocytes through the endothelium into the subjacent tissues—including both vascular smooth
muscle and, in the case of the coronary vessels, the underlying myocardium [5]. Furthermore,
distortion of vascular rheology from normal laminar flow patterns may result in dysfunction of the
endothelium, with associated further ROS release, and increased tissue expression of the alpha-arrestin
thioredoxin-interacting protein (TXNIP), which, inter alia, is an activator of the NLRP-3 (NOD-like
receptor family, pyrin domain-containing 3) inflammasome [6]. Thus, a pro-inflammatory cascade may
be amplified by neutrophil activation, with its final results within the heart including the development
of inflammatory changes in both endothelial and myocardial cells, as shown in Figure 1.
Resolution of neutrophil-associated inflammation is also a fundamental aspect of the return to
normal homeostasis: the “normal” “neutrophil burst” should be regarded as a transient response to
a chemical irritant (not necessarily a bacterium—microcrystals, such as uric acid may also initiate
the reaction). However, in practice, the resolution of tissue inflammation is sometimes slow, with a
resultant increase in the probability of permanent tissue injury. In the case of the heart, this would
involve apoptosis and necrosis of myocardial cells, and their eventual replacement by fibroblasts and
myofibroblasts. Similarly, loss of glycocalyx from coronary arteries and arterioles may theoretically
result in permanently disordered coronary vasomotor function. The clinical consequences may include
not only impairment of the vasomotor reactivity of the coronary vascular bed, but also continued
increases in vascular permeability, resulting in a propensity toward tissue oedema in the absence of
the normal haemodynamic determinants of its development.
It is important to appreciate that persistence of an inflammatory response within
neutrophil-infiltrated tissues represents a failure of normal neutrophil function. Many factors
contribute to the normal “pro-resolution” role of previously activated neutrophils, including the
expression of annexin-1 which promotes neutrophil apoptosis, anti-inflammatory chemokines such as
interleukin 10, and also scavenging chemokines and cytokines [7]. Neutrophil-derived microparticles,
released at the time of neutrophil activation, also play a part in the eventual reversal of this
process [8]. Furthermore, several groups have found that the pro-inflammatory effects of interleukin-1
beta (mediated via increased ROS production, primarily from NADPH oxidase) are prolonged by
S-glutathionylation of the p47phox component of the molecule [9].
The key point here remains the certainty that prolongation of leukocyte activation, irrespective of
mechanism, together with excessive initial activation are likely to exacerbate tissue injury, whether
in the myocardium, the vasculature or elsewhere. The remainder of this review will focus on
potential ways of limiting inappropriately severe and/or prolonged neutrophil-initiated tissue
inflammation, with particular reference to the role of BNP, before proceeding to briefly discuss some
forms of disease affecting the myocardium where this pathophysiological interaction may represent a
therapeutic opportunity.
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Figure 1. Cascade of intracellular and extracellular consequences of redox stress related to neutrophil
activation. SOD = superoxide dismutase; MPO = myeloperoxidase; TXNIP = thioredoxin-interacting
protein; NLRP3 = NOD-like receptor family, pyrin domain-containing 3.
1.2. Negative Modulation of Neutrophil Activation: The Role of cGMP Release
Neutrophils express nitric oxide synthases, which catalyse the generation of nitric oxide (NO)
from arginine, leading to the activation of soluble guanylate cyclase (sGC) and the generation of cGMP,
which is known to exert anti-inflammatory effects in general. However, it is also possible for excessive
release of NO to induce tissue injury in a cGMP-independent manner: –NO may also combine with
O2−, leading to the formation of peroxynitrite anion—which under conditions of rapid formation may
induce nitrosative stress via the nitrosation of protein tyrosine residues—and activation of the “energy
sink”/DNA reparative enzyme poly-(ADP/ribose) polymerase-1 (PARP-1)—which is implicated
in the impairment of myocardial contractility and the potential induction of heart failure [10,11].
The available literature concerning the impact of exogenous NO administration on the course of
neutrophil activation is relatively sparse. However, Klink et al. [12] have demonstrated a potentially
protective effect, mediated largely or entirely by inhibition of phosphorylation of the NADPH oxidase
subunit p47phox. On the other hand, there is evidence to suggest that NO may also accelerate this
effect, potentially leading to sustained inflammatory activation [13]. These findings are consistent with
the “Janus-type” effect of NO, perhaps dependent on the balance between sGC stimulation and the
formation of peroxynitrite anion. Gross increases in NO release, such as are associated with amplified
expression of inducible NO synthase in the presence of sepsis, might favour peroxynitrite-mediated
adverse effects.
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The other main source of potential activation of guanylate cyclase (but in this case particulate
guanylate cyclase [pGC]) in neutrophils is BNP, which is increasingly released into the systemic
circulation in a number of clinical disorders characterised by the presence of heart failure and/or
inflammatory activation. We have recently made a number of important observations concerning
interactions between BNP and neutrophil activation in a variety of heart failure syndromes [14,15].
These findings need to be set against a summary of the pathophysiology and biochemical effects of
BNP release.
1.3. Synthesis and Storage of BNP
Although BNP was initially purified from porcine brain extracts [16] and given the name “brain
natriuretic peptide”, the highest concentration of BNP is present in the heart [17]. As a primarily
cardiac hormone, BNP is mainly synthesised in and secreted from the left ventricle [18]. The BNP
gene encodes the prohormone proBNP. ProBNP is present in secretary granules within ventricular
myocardium: it is released into extracellular space in response to various stimuli and then cleaved to
BNP and the inactive N-terminal BNP fragment.
1.4. Release of BNP: Physiology and Pathology
In healthy subjects, mean BNP concentrations in venous blood are in the picomolar range.
Although BNP has a half-life of only about 20 min [19], plasma BNP concentrations do not generally
show rapid fluctuation. BNP secretion is largely controlled at the transcriptional level [20]. Prolonged
stimuli generally increase both rates of synthesis and of secretion [21]. Intense exercise produces
a moderate increase in plasma BNP concentration, and a greater exercise-related increase has been
observed in individuals with left ventricular hypertrophy or heart failure [22].
Although stretch and variable left ventricular wall tension are likely to be important in controlling
production and secretion of BNP, the precise mechanisms are still unclear. Increases in plasma BNP
concentrations are seen in several pathological states, such as hypertrophic cardiomyopathy, dilated
cardiomyopathy [23], and other forms of both systolic and diastolic heart failure [24]. Plasma BNP
concentration is also elevated in pulmonary hypertension, probably reflecting secretion from the right
ventricle [25]. Reduced oxygen tension has also been reported to stimulate BNP gene expression in
cultured ventricular myocytes [26], and this may also be relevant in the contexts of both pulmonary
hypertension and obstructive sleep apnoea.
There is also evidence that increased release of BNP may occur in the presence of myocardial
inflammation [27], despite minimal changes in cardiac distension. This will be discussed further in
relation to the condition of takotsubo syndrome.
Although the main source of circulating BNP is the heart, plasma levels of BNP can be affected by
extra-cardiac disease states and also by factors that affect clearance of the peptide, such as variation in
neutral endopeptidase (NEP) activity [28].
1.5. Physiological Actions of BNP
BNP acts through binding to natriuretic peptide receptor A (NPR-A, equivalent to particulate
guanylate cyclase-A [pGC-A]) which results in the generation of the second messenger cGMP [29].
This intracellular cGMP is believed to produce cellular and physiological responses by interacting with
cGMP-dependent protein kinases, cGMP-gated ion channels and cGMP-regulated cyclic nucleotide
phosphodiesterases (PDEs) [30]. This means that cGMP regulates a number of intracellular processes,
such as vascular smooth muscle relaxation [31], protection from oxidant damage [32], cellular
proliferation [33], Ca2+ handling by the sarcoplasmic/endoplasmic reticulum ATPase [34] and the
control of endothelial permeability [35]. Within the myocardium, it has recently been recognised that
cGMP, in the presence of protein kinase G, promotes relaxation of the myocardium via phosphorylation
of the sarcomeric titin molecule [36,37] which functions as a “giant spring.” Here, the resultant capacity
for incremental myocardial relaxation during diastole may have profound implications on myocardial
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perfusion, particularly in the sub-endocardium, via reduction of extramural compression of coronary
arteries during diastole.
On the other hand, BNP may function in parallel or in competition with NO, which also releases
cGMP through the activation of sGC [38], and thus maintains cardiovascular and renal homeostasis [39].
In recent studies, evidence has accumulated regarding the cross-talk between these two enzymes
(pGC-A and sGC) which represent “receptors” for BNP and NO, respectively [40].
In heart failure, BNP has numerous potentially beneficial effects, including diuretic, natriuretic,
vasodilating [41], renin-angiotensin system suppressing [41], anti-fibrotic and anti-hypertrophic
effects [41], as well as the inhibition of the synthesis of endothelin-1 [42]. In the presence of
chronic heart failure, acute intravenous infusion of BNP improves central hemodynamics, including
cardiac index, and also suppresses myocyte proliferation, cardiac growth, and compensatory cardiac
hypertrophy [42].
1.6. Clearance of BNP
BNP is degraded through two well-characterised processes: (1) NPR-C-mediated internalization
followed by lysosomal degradation; and (2) enzymatic degradation. It has been reported that the active
form of BNP (BNP1–32) can be degraded by dipeptidyl peptidase IV (DPP IV), NEP, meprin and insulin
degrading enzyme (IDE) to form BNP3–32, BNP5–32, BNP8–32 and smaller degradation peptides [43–45].
This cascade of events culminating in BNP release and associated vasodilatation is summarised in
Figure 2.
Figure 2. Cascade of BNP release and consequent physiological effects and clearance. BNP = B-type
natriuretic peptide; NPR-C = natriuretic peptide receptor C; NEP = neutral endopeptidase; DPP IV
= dipeptidyl peptidase IV; IDE = insulin degrading enzyme; pGC = particulate guanylate cyclase;
PDE = phosphodiesterase; GTP = guanosine triphosphate; cGMP = cyclic guanosine monophosphate.
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1.7. Circulating BNP Fragments
While it is known that BNP represents an enzymatic cleavage product of the 108-amino acid
precursor peptide proBNP, it has recently emerged that circulating BNP-like peptides include not only
BNP, but also proBNP and a range of inactive cleavage products of proBNP [46]. This has been most
intensely studied in acute heart failure, where most commercial BNP assay kits also detect several
of the non-BNP peptides [46]. However, the extent to which this also occurs in normal subjects is
less clear.
Specifically, molecular analysis of “assayed BNP” in subjects with acute heart failure reveals
two distinct peptides: a high-molecular weight form, proBNP1–108, and a low-molecular weight form,
the biologically active BNP1–32 [47]. There is substantial cross-reactivity of the commercially available
BNP and N-terminal pro B-type natriuretic peptide (NT-proBNP) assays with proBNP [46]. It appears
that compared to BNP and NT-proBNP, proBNP1–108—the intact precursor peptide—circulates at
high concentrations in patients with heart failure and may be the predominant form of circulating
natriuretic peptide. In addition, several breakdown products of BNP1–32 circulate as well, and most
of these degradation fragments of BNP1–32 are also detected by commercial BNP assays. Overall,
it appears that there is relatively little bioactive BNP (BNP1–32) in the plasma of heart failure patients.
These findings suggest there are abnormalities in the cleavage of proBNP1–108 to BNP1–32 in the
presence of heart failure, but also do not permit evaluation of BNP1–32 concentrations within the
myocardial interstitial space.
2. BNP Suppression of Neutrophil ROS Formation: “BNP Resistance”
The concept that the anti-inflammatory effects of BNP might be related, in whole or part,
to the suppression of ROS formation by neutrophils was previously investigated by our group [48].
We initially studied normal subjects to determine the effects of exogenous BNP on the “neutrophil burst”
and associated myeloperoxidase (MPO) release. In this circumstance, BNP suppressed O2− release,
apparently in a cGMP/PKG-dependent manner (although no significant change in cGMP generation
was detected). On the other hand, BNP did not affect MPO release. These data therefore suggested
that under physiological conditions, BNP acts as a negative modulator of the “neutrophil burst.”
The potential consequences of this interaction might include reduction in the extent of extracellular
redox stress associated with neutrophil activation, and therefore the limitation of consequent tissue
injury. The impact of exogenous BNP on the process of resolution of neutrophil activation was
not explored.
Subsequently, we sought to evaluate whether this “protective” effect of BNP might vary under
conditions of acute myocardial inflammation, which particularly occur in patients with heart failure of
recent onset. We compared the impact of exogenous BNP on the “neutrophil burst” in healthy subjects
and in patients with acute heart failure. In the latter group, the impact of BNP in suppressing O2−
release was substantially diminished (Figure 3), and in association with this, it was found [14,48] that
BNP inhibited phosphorylation of the NADPH oxidase subunit p47phox (and consequent activation
of NADPH oxidase) only in normal subjects (Figure 4). These observations therefore implied that
acute heart failure is associated with impairment of the anti-oxidant effects of BNP at the neutrophil
level, leading to net increases in the formation of O2− and its potential extracellular release, and thus
rendering patients more prone to tissue injury. Interestingly, this “BNP resistance” partially resolved
over a mean period of five weeks of anti-failure therapy. Furthermore, while we did not explore
whether greater infiltration of myocardium with leukocytes in heart failure might reflect poor tissue
responsiveness to BNP, this has been suggested by previous investigations by Kawakami et al. [49].
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Figure 3. Comparison of BNP effects on phorbol 12-myristate 13-acetate (PMA)-stimulated (A) and
N-formyl-methionyl-leucyl-phenylalanine (fMLP)-stimulated (B) O2− generation by neutrophils from
acute heart failure patients (n = 45) and control subjects (n = 29). (C,D) Raw data for actual O2−
production in neutrophils from acute heart failure patients (C) and control subjects (D). * p < 0.05 [14].
Figure 4. Effect of BNP on phosphorylation of p47phox Ser345. (A) In acute heart failure patients (n = 9)
there is attenuation of BNP-induced suppression of p47phox Ser345 phosphorylation stimulated by
N-formyl-methionyl-leucyl-phenylalanine (fMLP), which is seen in neutrophils from healthy subjects
(n = 7). The relative ratio of p47phox Ser345 to total p47phox for samples treated with fMLP was taken
as control (100%). * p < 0.05. (B) Representative immunoblots of acute heart failure patients and control
subjects. Note suppression of phosphorylation of Ser345 by BNP in control subjects but not acute heart
failure patients [14].
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3. Is BNP Synergistic with NO?
Unfortunately, the potential existence of interactions between the NO/sGC and the BNP/pGC
systems has received little attention to date. Theoretically, NO, which also inhibits NADPH oxidase
assembly [50] might augment the effects of BNP in limiting the “neutrophil burst” and the associated
release of ROS. On the other hand, NO may also initiate sGC-independent pathophysiological effects,
such as extensive protein nitrosation and activation of the “energy sink” enzyme PARP-1 [11]. Clearly
this area merits further investigation. Furthermore, expression of the inducible form of NOS (iNOS),
leading to massive increases in NO release, may represent a special case which may be of relevance to
patients with sepsis.
4. Potential Clinical Implications
The abovementioned findings have a number of clinically relevant therapeutic implications. It is
clear that BNP acts as a substantial negative modulator of O2− release by neutrophils, and lacks
the potential (peroxynitrite-mediated) negative implications of marked release of NO within the
myocardium. Therefore, BNP would tend to limit tissue injury associated with excessive activation of
NADPH oxidase.
There are a number of acute and chronic cardiac disorders which are characterised by the
presence of myocardial infiltration by neutrophils, with associated tissue inflammation, and with both
the marked release of BNP and the activation of glycocalyx shedding—a result of the impact of a
range of matrix metalloproteinases [5]. These include, in particular, acute myocardial infarction [51]
and takotsubo syndrome [52], a catecholamine-initiated form of acute myocardial inflammation.
In both of these conditions, myocardial infiltration by neutrophils and monocyte/macrophages is
prominent. In patients with acute heart failure, including those without significant myocardial
ischaemia, BNP release is marked, and this remains the case to a latter extent in chronic heart failure,
where persistence of myocardial inflammation is also a frequent finding [53].
Indeed, in takotsubo syndrome, BNP release occurs to extraordinary extents, especially compared
with the usually minor elevation of left ventricular filling pressures. These findings suggest that in this
condition in particular, BNP may be released mainly in response to the beginning of intra-myocardial
inflammation, which is particularly intense in the early stages of takotsubo syndrome. On the
other hand, it is likely that excessive NO release and effects—including the induction of nitrosative
stress [54]—are also relevant to the development of myocardial inflammation in such patients. A major
problem in the early stages of takotsubo syndrome is the development of hypotension and shock,
and it is certainly possible that effective infusion of BNP, rather than of NO, might provide a means
for limiting the extent of myocardial inflammation and the resultant prolonged impairment of left
ventricular function.
Counter-intuitively, infusion of the BNP analogue nesiritide has been found to be of little use in
the treatment of acute heart failure [55]. This lack of effect implies tissue resistance to the biochemical
and/or physiological effects of BNP in this circumstance, consistent with our observations regarding
the interactions of BNP with the “neutrophil burst” [14]. However, it is surprising that therapeutic
response to nesiritide remains poor despite relatively high infusion rates.
Importantly, it is not yet clear whether impairment of responses to BNP, other than inhibition of
the “neutrophil burst,” occurs in either heart failure (acute/chronic; systolic/diastolic) or takotsubo
syndrome. Specifically, it would be of advantage to know to what extent the vasodilator and
anti-inflammatory effects of BNP might be compromised in these conditions.
The issue may be particularly important in heart failure with a preserved ejection fraction, a very
common condition in ageing individuals, and one in which it has been postulated that ongoing systemic
inflammatory activation may be critical to the development and perpetuation of heart failure [37].
It must be noted that, thus far, the medical literature on the limitation of chronic myocardial and
coronary microvascular inflammation is fragmentary, but progress in quantitation of myocardial
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inflammation and resultant oedema utilizing cardiac magnetic resonance imaging should facilitate the
extension of clinically-based investigations in this area.
These findings have a number of potential therapeutic sequelae. It seems likely, but not yet
certain, that impairment of tissue responsiveness to BNP may result from the impact of oxidative
stress on activity of pGC. Hence, two potential therapeutic avenues are theoretically available to limit
myocardial and coronary vascular endothelial injury induced by “BNP resistance.” First, therapy with
agents known to limit activation of NADPH oxidase, such as ACE inhibitors and perhexiline [56] has
already been shown to be useful, although the contribution of BNP potentiation to salutary effects at
the level of clinical end-points has not yet been explored. Second, there is evidence that degradation of
BNP by NEP within neutrophils may limit its effectiveness [57]. Hence, the increasing clinical use of
therapy, including NEP inhibitors, in the management of chronic heart failure [58] may be regarded
as a potential first step toward the additional utilization of such therapy in the treatment of acute
cardiac emergencies.
5. Conclusions
The “neutrophil burst” represents a pivotal component of innate immune defense against invading
micro-organisms, but also a cause of “collateral tissue damage” via extracellular effects of the O2−
anion radical. In the heart, release of O2− induces tissue injury (both myocardial and microvascular),
as is seen in many forms of acute heart failure. Takotsubo syndrome provides a particularly apposite
example of this cascade of events. Moreover, failure of resolution of neutrophil activation can lead
to progressive worsening of tissue damage. BNP appears to function physiologically as a negative
modulator of the “neutrophil burst,” which thus may limit resultant tissue injury. However, this
protective effect is lost during the acute phase of heart failure. We propose that optimizing the
efficacy of BNP as a counterbalance against neutrophil activation represents a theoretically promising
therapeutic strategy to treat or prevent heart failure.
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Abbreviations
BNP B-type natriuretic peptide
DPP IV Dipeptidyl peptidase IV
fMLP N-formyl-methionyl-leucyl-phenylalanine
HOCl Hypochlorous acid
IDE Insulin degrading enzyme
MPO Myeloperoxidase
NEP Neutral endopeptidase
NET Neutrophil extracellular trap
NLRP3 NOD-like receptor family, pyrin domain-containing 3
NPR-A Natriuretic peptide receptor A
NPR-C Natriuretic peptide receptor C
NO Nitric oxide
O2− Superoxide anion radical
PARP-1 poly-(ADP/ribose) polymerase-1
PDE Phosphodiesterase
pGC Particulate guanylate cyclase
PMA Phorbol 12-myristate 13-acetate
ROS Reactive oxygen species
sGC Soluble guanylate cyclase
SOD Superoxide dismutase
TXNIP Thioredoxin-interacting protein
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